不同剂量阿司匹林在冠心病行经皮冠状动脉介入术后的应用效果

目的探讨不同剂量阿司匹林在冠心病行经皮冠状动脉介入术（PCI）后的应用效果。方法选取本院2011年2月-2013年2月行PCI的202例冠心病患者为研究对象,简单抽样法随机分为A、B两组,每组101例,A组给予低剂量阿司匹林（0.1 g/d）,B组给予高剂量阿司匹林（0.3 g/d）。比较两组治疗后6个月随访期内不良脑血管事件发生情况,记录其各项指标的变化情况。结果两组治疗前各项指标比较,差异无统计学意义（P〉0.05）;治疗后6、12个月各指标均较治疗前明显降低（P〈0.05）;A、B两组治疗后6、12个月血栓烷B2及总胆固醇组间比较,差异无统计学意义（P〉0.05）;治疗后6个月,B组三酰甘油（TG）及低密度脂蛋白胆固醇（LDL-C）水平明显低于A组,差异有统计学意义（P〈0.05）;治疗后12个月两组各项指标均较治疗6个月后降低,但差异无统计学意义（P〉0.05）。治疗后A组不良脑血管事件发生率为13.86%,B组为15.84%,两组差异无统计学意义（χ2=0.69,P〉0.05）。结论对冠心病患者行PCI后给予低剂量阿司匹林,可有效降低不良脑血管事件发生率,安全性较高,具有临床推广价值。

Effect of different doses of aspirin in the treatment of coronary heart dis-ease after percutaneous coronary intervention

Objective To explore the application effect of different doses of aspirin in coronary heart disease after per-cutaneous coronary intervention （PCI）. Methods 202 patients with coronary heart disease,who received PCI in our hos-pital from February 2011 to February 2013 were chosen as the research objects and were randomly divided into group A and group B according to random table method,101 cases in each group.Group A were treated with low dose of as-pirin （0.1 g/d） while group B were treated with high dose of aspirin （0.3 g/d）.The occurrence of adverse cerebrovascular events during the 6 month follow-up period were compared between two groups after treatment and its changes were recorded. Results The indexes in two groups before treatment had no significant difference （P〉0.05）,and all indexes of the two groups six and twelve months after treatment were lower than those before treatment （P〈0.05）;After six months treatment,TG and LDL-C in group B was lower than that in group A,the difference was significant （P〈0.05）;The indica-tors of two groups after 12 months treatment were decreased compared with 6 months treatment,but the difference was not significant （P〉0.05）.The incidence rate of adverse cerebrovascular events after treatment in group A was 13.86%, compared with 15.84%in group B,the difference was not significant （P〉0.05）. Conclusion Giving a small amount of as-pirin to patients with coronary heart disease patients after PCI can effectively reduce the incidence of adverse cere-brovascular events and has high security.This method has clinical value.